Imaging Agents: Market Research Report

Date: January 9, 2016
Pages: 384
Price:
US$ 4,950.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: I7AE5BCAD07EN
Leaflet:

Download PDF Leaflet

Imaging Agents: Market Research Report
This report analyzes the worldwide markets for Imaging Agents in US$ by the following Product Segments: Contrast Media (X-Ray/CT, MRI, & Ultrasound), and Diagnostic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs. The report profiles 53 companies including many key and niche players such as -
  • Aytu BioScience, Inc.
  • Bayer Healthcare Pharmaceuticals
  • Bracco Diagnostics, Inc.
  • Daiichi Sankyo Company Limited
  • Eisai Co., Ltd.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
A. Contrast Media
X-Ray/CT Contrast Media
Magnetic Resonance Imaging (MRI) Contrast Media
Ultrasound Contrast Media
B. Diagnostic Radiopharmaceuticals

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

Imaging Agents: A Quick Primer
Market Outlook
Current and Future Analysis
Analysis by Region
United States: Holds the Largest Share
Developing Countries: Potentially Lucrative Market
Analysis by Segment
Contrast Media: Giving Way to Contemporary Offshoots
Diagnostic Radiopharmaceuticals to Outdo Contrast Media
Nuclear Medicine: A Potential Growth Avenue for Dx Radiopharmaceuticals
Select PET and SPECT Radioisotopes Used in Nuclear Medicine
Select Cardiology and Oncology Radiopharmaceuticals
Major Growth Drivers in a Gist
Select Market Growth Restraints

2. SEGMENTAL OVERVIEW AND COMPETITIVE LANDSCAPE

Market Structure
Key Market Participants
Contrast Media
Popular Brands of Contrast Agents
X-ray Contrast Media

Table 1. Annual Sales of Select Key Iodinated Contrast Agents: 2014 & 2015 (In US$ Million) (includes corresponding Graph/Chart)

MRI Contrast Media
Market Scenario
Key Players in the MRI Market
List of FDA Approved Gadolinium-Based Contrast Agents (GBCA) for CNS MR
List of EMA Approved Gd Chelated Contrast Agents
Controversies over GBCAs Refuse to Die Down
A Comparison of Approved Gadolinium-based Contrast Agents
Select GBCA-Induced Toxicities
Regulators Spring into Action
European Medicines Agency’s NSF Risk-based Classification of GBCAs
Competitive Re-arrangement Surfaces as Safety Concerns on GBCAs Reach their Peak

Table 2. Annual Sales of Select Key Gadolinium-Based Contrast Agents: 2014 & 2015 (In US$ Million) (includes corresponding Graph/Chart)

Glucose – Can it Replace GBCAs?
Ultrasound Contrast Media
Limited System Use Curtails Demand for Ultrasound Contrast Agents; Potential for Further Growth Exists
CEUS and Ultrasound Contrast Agents – A Dichotomy in Approach in Europe and the US
A Comparison of Major Approved UCAs
Approved Ultrasound Contrast Agents by Country and Application
Contrast Media API Production – Still Largely In-house
A Peek into API Supplier Space for Select Contrast Media
Diagnostic Radiopharmaceuticals
Market Overview
Commonly Used Diagnostic Radiopharmaceutical Agents
Major Isotopes and their Diagnostic Applications
Select FDA Approved Diagnostic Radiopharmaceuticals by Indication
New Imaging Agent for Radiopharmaceutical Scans
Prospects for Radiopharmaceutical Agents in PET and SPECT Appear Brighter

3. MARKET TRENDS & ISSUES

Expansion of Molecular Imaging Platform is Key to Future Growth
Growing Interest in Image Guided Surgery Offers New Opportunities
Fluorescence Optical Imaging – Opens New Avenues
Coronary CT Angiography Opens Up Opportunities for Contrast Agents
List of Iodine-Containing Contrast Agents for Coronary CT Angiography
Targeted Imaging – A Game Changer in the Making?
Clinical Acceptance of MRI Systems on Rise
Nanomaterials Taking the Center Stage
New Nanoparticle Contrast Agents on the Horizon Show Promise
Gadolinium Coated Nanoparticles - A Promising Imaging Agent
Growing Focus on Development of Gold Nanoparticles in X-Ray Imaging
Imaging Agents Make a Welcome Impact in the Field of Alzheimer’s Disease
List of FDA Approved Alzheimer's Diagnostic Imaging Agents
Contrast-Enhanced Tomosynthesis Expands Opportunities
Hyperpolarized Gases as Contrast Agents
Multi-Modal Imaging: Combating Contrast Medium Inconsistencies
Falling Prices Turn on the Heat
Ultrasound Contrast Agents in Diagnosis of Kidney Ailments
FDA Mandates Black Box Warning Label for Gadolinium-Based MRI Contrast Agents
PET: A Prime Growth Driver for Diagnostic Radiopharmaceuticals
Innovative Radiotracers to Boost Cardiac Applications for SPECT and PET Modalities
Global CVD Stats

Table 3. Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart)
Table 4. Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart)

Opportunities on Rise for Fluorine-Based Myocardial Perfusion Agents
Unfounded Fears of Radiation Exposure: A Major Concern for Nuclear Diagnostics
Rising Incidence of Cancer – A Major Growth Driver
World Cancer Statistics – Incidence and Mortality Data

Table 5. World Cancer Incidence by Geographic Region (2012): Number of New Cancer Cases Reported in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)
Table 6. World Cancer Mortality by Geographic Region and Gender (2012): Number of Cancer-Related Deaths in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)

Improving Healthcare Expenditure to Foster Growth

Table 7. Healthcare Spending as % of GDP by Region (2016E) (includes corresponding Graph/Chart)
Table 8. Healthcare Spending as a Percentage of GDP in Select Countries (2013) (includes corresponding Graph/Chart)
Table 9. Per-Capita Healthcare Spending in Select Countries (2013) (includes corresponding Graph/Chart)

Ageing Population – A Vital Demography

Table 10. Percentage Growth of 65+ Population in North America, Europe, Asia, and Latin America (includes corresponding Graph/Chart)
Table 11. Global Population Statistics for the 65+ Age Group (2015) (includes corresponding Graph/Chart)
Table 12. Comparison of Aging Population by Country (1980, 2015 & 2050): Percentage Share of Population Aged Above-65 Years of the Overall Population for Select Countries (includes corresponding Graph/Chart)
Table 13. Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart)

A Peek into Pricing Dynamics
A Synoptic Overview
Pros & Cons
Positive Factors Driving Prices
Negative Factors Bearing Down on Prices
Reimbursements
Europe
United States

4. GLOBAL MEDICAL IMAGING MARKET – AN OVERVIEW

Medical Imaging – Changing the Landscape of Clinical Diagnosis

Table 14. Global Imaging Equipment Market by Modality (2015): Percentage Breakdown of Value for CT, MRI, Nuclear, Ultrasound and X-Ray (includes corresponding Graph/Chart)
Table 15. Global Imaging Equipment Market by Geographic Region (2015): Percentage Breakdown of Value for China, Europe, Japan, North America and Rest of World (includes corresponding Graph/Chart)
Table 16. Global Medical Imaging Equipment Installed Base (2013): Percentage Share Breakdown of Volume Installations for X-ray, Ultrasound, Magnetic Resonance, Computed Tomography, and Nuclear Medicine/PET by Country/Region (includes corresponding Graph/Chart)

Comparison of Modalities by Various Imaging Systems
Archaic X-Ray Imaging Modalities Paving Way for Digital X-Rays
Ultrasound Holds its Fort in the Medical Imaging Market

Table 17. World Ultrasound Market by Application (2015): Percentage Breakdown of Usage for Cardiology, Radiology and Others (includes corresponding Graph/Chart)

Technological Advancements Favor MRI Market

Table 18. Global MRI Usage by Application Area (2013) (includes corresponding Graph/Chart)

Comparison of MRI against Other Imaging Modalities
Nuclear Medicine Imaging Equipment Presents Lucrative Growth Opportunities

Table 19. Worldwide Installed Base of Nuclear Imaging Devices by Modality (2013) Percentage Share Breakdown of Number of Installations for SPECT and PET (includes corresponding Graph/Chart)

Hybrid Imaging to Herald a New Era of Diagnosis
Hybrid PET/MRI Systems: A New Fusion
Price Sensitivity & Competition from Alternatives Limit Market Potential
Unfounded Fears of Radiation Exposure Hinder Growth
Bottlenecks in Developing Markets
Use of Contrast Agents in Other Imaging Modalities
Fluoroscopy
Computed Tomography

5. PRODUCT OVERVIEW

Contrast Agents
Contrast Media: How Do They Function?
Where Are They Used…?
Evolution of Contrast Media: A Profile
Bismuth Nitrate: Beginning of Contrast Agents
Imaging Agents: Significant Developments in the Last Fifty Years
Schering Develops First Intravenous Contrast Agent
MRI: Creating a New Era for Contrast Agents
A Peek into the Finer Points of Differences Among Contrast Media
Second Generation Non-Ionic Contrast Agents: An Introduction
Choice of the Contrast Medium: A Weighty Decision
Factors Affecting choice of Imaging Agents
Taxonomy
Types of Contrast Media
X-Ray Contrast Medium
First Generation High Osmolar Contrast Media
Second Generation Low Osmolar Contrast Media or LOCM

Table 20. Comparative Analysis of Structure of Non-ionic and ionic X-ray Contrast Media

MRI Contrast Medium
Role of Contrast Enhancement in MR Angiography (MRA)
MRI Contrast Agents for the Liver
Paramagnetic Extracellular Contrast Agents
Hepatobiliary Gadolinium Chelates
Superparamagnetic Iron Oxide Particles
Ultrasound Contrast Medium
Ultrasonographic Contrast Media: What Are They?
Ultrasound Contrast Enhancement in Cardiology
Functionalities of Vascular Ultrasound Contrast Agents
Diagnostic Radiopharmaceuticals
A Delineate of Diagnostic Radiopharmaceuticals
Diagnostic Radiopharmaceuticals: A Technical Run-Through
Applications
Classification
Cardiology Diagnostics
Non-cardiology Diagnostics
Molecular Imaging Modalities in Radiopharmaceutical Diagnostics
Planar Imaging
Positron Emission Tomography (PET)
Applications of PET
Commonly used Radioisotopes in PET Scans
Major PET Isotopes and their Applications
Single Photon Emission Computed Tomography (SPECT)
Applications of SPECT
Commonly used Radioisotopes in SPECT Scans

6. TECHNOLOGY DYNAMICS

Proprietary Technologies Making In-Roads
Advanced Magnetics’ Proprietary Colloidal Superparamagnetic Particle Technology
Enzon’s Single Chain Antigen-Binding Technology
Immunomedics’ Antibody Technology
First Generation
Second Generation
Third Generation
NeoRx’s “Painting the Target” Technology
Stage
Stage
Stage
Gas Encapsulation Technology for Ultrasound Contrast Media
Pharmacyclics’ Texaphyrin Technology
Regulatory Bodies
Entry Barriers
Research Driven Markets
Highly Competitive Market
Economies of Scale
Substitutes in Agents Manufacturing
New X-ray Diagnostic Agents
Amide-based Macrocyclic Ligands – Potential MRI Agents
Gadolinium (III) Complexes – Potential MRI Contrast Agents
Metal-Containing Compounds Act As Potential Contrast Agents
Therapeutic Applications
Diagnostic Applications
Magnetic Gels as Potential MRI Contrast Agents
PFCs as Diagnostic Contrast Agents
Saline Flushes To Help Ensure Accurate Delivery of Contrast Agents

7. PRODUCT LAUNCHES/APPROVALS/ CLINICAL TRIALS

Lantheus Begins Shipment of Xenon Xe 133 Gas
Otsuka Launches ORALTAG in the US
Advanced Accelerator Applications Receives FDA Approval for Netspot
Blue Earth Diagnostics Secures FDA Approval for Axumin
Bayer Obtains FDA Approval for Gadavist for MRA for Supra-aortic Arteries
Bracco Secures FDA Clearance for LUMASON in Ultrasonography of the Liver for Lesion Characterization
Bracco Obtains FDA Clearance for READI-CAT 2 and READI-CAT 2 SMOOTHIE NDA
Bracco Bags FDA Approval for E-Z-HD for GI Tract Radiohraphic Exams
Bracco Imaging Rolls Out EmpowerCTA+ Contrast Injection System
Bayer Obtains Label Extension for Gadovist in the EU
Bayer Receives Approval for Gadovist for Use with MRI in Japan
Bayer Secures FDA Approval for Gadavist for Use in Infants
Bracco Makes ISOVUE Available for POC Use in CT Suite
Bracco Bags FDA Clearance for Lumason for Suboptimal Echocardiograms in Adults
GE Introduces Vizamyl Alzheimer's Imaging Agent
Navidea Biopharmaceuticals Obtains FDA Approval for Lymphoseek Injection for New Indication
Bayer Obtain FDA Approval for Gadavist for Breast Cancer Evaluation
GE Healthcare Gets Norwegian Medicines Agency Approval for Sonazoid to Detect Focal Liver Lesions
ImaginAb Announces Initial Phase I/IIa Results for 89Zr-Df-IAB2M Prostate Imaging Agent
Piramal Imaging Receives FDA Approval for Neuraceq PET Imaging Agent
NanoHybrids Introduces Premium Product Line of Imaging Contrast Agents
CMC Contrast AB Obtains Orphan Drug Designation from the US FDA for CMC
GE Healthcare Obtains FDA Approval for its Oslo Plant to Manufacture Optison Heart Imaging Agent
GE Healthcare Gets FDA Approval for Vizamyl Alzheimer's Imaging Agent
GeccoDots Launches New Contrast Agent
Navidea Biopharmaceuticals Signs Agreement with Nordion
Navidea Biopharmaceuticals Launches Lymphoseek
GE Healthcare Gets Expanded FDA Approval for AdreView
Guerbet Obtains FDA Approval for Dotarem MRI Contrast Agent
PerkinElmer Introduces GFR-Vivo
Navidea Obtains FDA Approval for Lymphoseek Injection
Navidea Signs Agreement with Maimonides Medical Center to Collaborate on Clinical Trial Utilizing Lymphoseek Injection in Colorectal Cancer

8. RECENT INDUSTRY ACTIVITY

Cell>Point Inks Licensing Agreement with UEP for Oncardia
FluoroPharma Inks Agreement to Take Over Ground Fluor Pharmaceuticals
Bracco Diagnostics’s LUMASON Obtains Innovative Technology Designation from Vizient
Blue Earth Diagnostics Establishes Operations in the US
Ipsen and 3B Pharmaceuticals Ink Licensing Deal for Oncology Radiopharmaceuticals
Lantheus Divests Gludef Business in Canada to Isologic
Guerbet Acquires Mallinckrodt’s Contrast Media and Delivery Systems Business
Bracco Obtains CMS Pass-Through Status for its Lumason Ultrasound Contrast Agent
Guerbet Inks Deal with Beijing Kyuan Pharmaceutical for Lipiodol Ultra-Fluid
Bracco Expands Group Purchasing Agreement with Amerinet to Include Lumason
Guerbet Inks Agreement with Fuji Pharma to Distribute Contrast Media in Japan
Bayer Inks Agreement with Polysan to Produce Contrast Media in Russia
Blue Earth Diagnostics’ Fluciclovine (18F) Obtains Orphan Drug Designation for Glioma Diagnosis in US and Europe
Aytu BioScience Acquires ProstaScint from Jazz Pharmaceuticals
PETNET Solutions Inks Agreement with Blue Earth Diagnostics for Fluciclovine Manufacture and Distribution
Ipsen to Acquire OctreoPharm Sciences
IBA Molecular to Divest US Operations to Illinois Health and Science
Lantheus Obtains sNDA from FDA for Manufacturing NEUROLITE at Jubilant HollisterStier
Lantheus Inks Supply Agreement for Xenon 133 with IRE
AAA to Acquire GE’s Italian FDG-PET Imaging Agent Business
ImaginAb Establishes Subsidiary in Japan
ImaginAb and Duke-NUS Partner to Develop in vivo Molecular Imaging Agents
AC Immune and Piramal Imaging Strike Deal to Develop Alzheimer's Imaging Agent
Blue Earth Diagnostics Commences Operations
Enlyton Bags SBIR Contract from NCI for Pre-Clinical Development of Tumor Imaging Agent
Guerbet Obtains FDA Approval for Lipiodol Contrast Agent Manufacturing Plant
Integrated Diagnostics Launches InDi Molecular
Endocyte Signs Licensing Agreement with Endocyte for etarfolatide Cancer Diagnostic Imaging Agent
Siemens’ PETNET Solutions Signs Agreement with Navidea Biopharmaceuticals
Eli Lilly to Acquire two Alzheimer's Imaging Agents from Siemens
Siemens PETNET Solutions Expands Manufacturing and Distribution of Amyvid

9. FOCUS ON SELECT PLAYERS

Aytu BioScience, Inc. (US)
Bayer Healthcare Pharmaceuticals (Germany)
Bracco Diagnostics, Inc. (US)
Daiichi Sankyo Company Limited (Japan)
Eisai Co., Ltd. (Japan)
Eli Lilly and Company (US)
GE Healthcare (UK)
Guerbet Group (France)
Lantheus Medical Imaging, Inc. (US)
Mallinckrodt plc (Ireland)

10. GLOBAL MARKET PERSPECTIVE

Table 21. World Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 22. World Historic Review for Imaging Agents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 23. World 14-Year Perspective for Imaging Agents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
Table 24. World Recent Past, Current & Future Analysis for Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 25. World Historic Review for Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 26. World 14-Year Perspective for Contrast Media by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
Table 27. World Recent Past, Current & Future Analysis for Contrast Media by Product Segment - X-Ray/CT, MRI and Ultrasound Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 28. World Historic Review for Contrast Media by Product Segment - X-Ray/CT, MRI and Ultrasound Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 29. World 14-Year Perspective for Contrast Media by Product Segment - Percentage Breakdown of Dollar Sales for X-Ray/CT, MRI and Ultrasound Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
Table 30. World Recent Past, Current & Future Analysis for X-Ray/CT Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 31. World Historic Review for X-ray/CT Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 32. World 14-Year Perspective for X-Ray/CT Contrast Media by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
Table 33. World Recent Past, Current & Future Analysis for MRI Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 34. World Historic Review for MRI Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 35. World 14-Year Perspective for MRI Contrast Media by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
Table 36. World Recent Past, Current & Future Analysis for Ultrasound Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 37. World Historic Review for Ultrasound Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 38. World 14-Year Perspective for Ultrasound Contrast Media by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
Table 39. World Recent Past, Current & Future Analysis for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 40. World Historic Review for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 41. World 14-Year Perspective for Diagnostic Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. Market Analysis
Contrast Media Market to Witness Slow but Steady Growth

Table 42. US Contrast Media Market by Leading Players (2013): Percentage Dollar Share Breakdown for Bayer, Bracco, GE Healthcare, Mallinckrodt and Others (includes corresponding Graph/Chart)

Diagnostic Radiopharmaceuticals to Drive Future Growth

Table 43. US Nuclear Imaging Market (2015): Percentage Share Breakdown of Procedure Volume for SPECT and PET (includes corresponding Graph/Chart)
Table 44. US Market for Diagnostic Radiopharmaceuticals Agents (2015E): Percentage Share Breakdown of Value Sales for Cardiology and Non-Cardiology Applications (includes corresponding Graph/Chart)

Growth Stimulants in a Nut Shell
Demographic Changes Offer Growth Opportunities

Table 45. North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)

Dynamics of Pricing
Key Trends and Issues
Expanding Applications to Stimulate Growth in Dx Radiopharmaceuticals Market
New Oncology, Neurology Agents to Boost Growth
Managing Alzheimer’s Opens New Avenues for Imaging Agents
List of FDA Approved Alzheimer's Diagnostic Imaging Agents
Alzheimer’s Stats

Table 46. Alzheimer’s Prevalence in the US (2015): As a Percentage of Population by Age-Group (includes corresponding Graph/Chart)
Table 47. Alzheimer’s Prevalence in the US by State: 2016 & 2025 (includes corresponding Graph/Chart)

Nuclear Cardiology Products Drive Diagnostic Radiopharmaceuticals Market
Cardiovascular Imaging to Lead Volume Growth
PET Procedures in the US on Rise

Table 48. US PET Market by Leading Players (2013): Percentage Market Share Breakdown of Value Sales for GE Healthcare, Philips Healthcare, Siemens Healthcare and Others (includes corresponding Graph/Chart)

Growing Adoption of SPECT/CT
Rising Incidence of Cancer – A Major Growth Driver

Table 49. New Cancer Cases by Gender and Affected Site in the US (2015) (includes corresponding Graph/Chart)

Isotope Shortage Leads to Dependence on Imports
Shortage of Medical Isotopes Looms Large

Table 50. Nuclear Reactors Producing 99Mo: Potential Annual Output and Estimated Year of Ceasing Production (includes corresponding Graph/Chart)
Table 51. National Programs for New Molybdenum 99 Capacity: Annual Production Estimates and Current Status

DOE’s Flawed Isotope Program Adds to the Woe
US Fluorodeoxyglucose (FDG) Market: An Overview

Table 52. US FDG Market by Procedure Type (2012): Percentage Share Breakdown of Procedure Volume for Oncology, Neurology, and Cardiology (includes corresponding Graph/Chart)

Competitive Analysis – Imaging Market
Regulatory Environment
Provisions Regarding Off-Label Usage of Contrast Media
Reimbursement Issues
Contrast Agents and Diagnostic Radiopharmaceuticals Bundled As Supplies

Table 53. CT Reimbursement Changes: CPT Codes for CT and CT Angiography and Payment Rates for 2015 and
Table 54. MRI Reimbursement Changes: CPT Codes for MRI and MR Angiography (MRA) and Payment Rates for 2015 and

Product Launches/Approvals
Strategic Corporate Developments
Key Players
B. Market Analytics

Table 55. US Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 56. US Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 57. US 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

2. CANADA

A. Market Analysis
Current and Future Analysis
An Overview of Medical Imaging Market

Table 58. Percentage Distribution of Canadian Population by Age Group: 2015 (includes corresponding Graph/Chart)

Canadian Scientists Discover Remedy for Isotope Shortages
Regulatory and Legal Restrictions
Strategic Corporate Developments
B. Market Analytics

Table 59. Canadian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 60. Canadian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 61. Canadian 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

3. JAPAN

A. Market Analysis
Current and Future Analysis
Demographics Drive Market Growth

Table 62. Japanese Population by Age Group (2015) (includes corresponding Graph/Chart)
Table 63. Japanese 65+ Years Population: 1950-2010 (includes corresponding Graph/Chart)

Number of Nuclear Medicine Procedures on the Rise
Reimbursement Issues
Product Approval
Strategic Corporate Developments
Key Players
B. Market Analytics

Table 64. Japanese Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 65. Japanese Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 66. Japanese 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4. EUROPE

A. Market Analysis
Outlook
Nuclear Medicine Imaging Equipment Market: An Overview

Table 67. European Installed Base for Diagnostic Imaging Equipment by Modality (2013): Percentage Share Breakdown of Volume Installations for SPECT, PET/CT, SPECT/CT, Planar, Cardiac SPECT, and PET/MR (includes corresponding Graph/Chart)

Cancer: A Major Driver for Diagnostic Radiopharmaceuticals

Table 68. Cancer Incidence in Europe by Site: 2012 (in Thousands) (includes corresponding Graph/Chart)

Ageing Demography – An Opportunity Indicator

Table 69. Population Breakup by Age Group for EU-28 Countries: 2015 (as a Percentage of Total Population) (includes corresponding Graph/Chart)

Reimbursement
Outsourcing of Imaging Diagnostics
Distribution Structure
Direct Sales
License Agreements
Distribution Agreements
A Price Sensitive Market
Macro Environment
Germany
France
Spain & Italy
Scandinavia
Product Approval
B. Market Analytics

Table 70. European Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 71. European Historic Review for Imaging Agents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 72. European 14-Year Perspective for Imaging Agents by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
Table 73. European Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 74. European Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 75. European 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4A. FRANCE

A. Market Analysis
Current and Future Analysis
Growth Stimulants
Strategic Corporate Developments
Guerbet Group – A Key Player
B. Market Analytics

Table 76. French Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 77. French Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 78. French 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4B. GERMANY

A. Market Analysis
Current and Future Analysis
Strategic Corporate Development
Bayer Healthcare Pharmaceuticals – A Key Player
B. Market Analytics

Table 79. German Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 80. German Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 81. German 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4C. ITALY

A. Market Analysis
Current and Future Analysis
Strategic Corporate Development
B. Market Analytics

Table 82. Italian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 83. Italian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 84. Italian 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4D. THE UNITED KINGDOM

A. Market Analysis
Current and Future Analysis
Strategic Corporate Development
GE Healthcare – A Major UK-Based Player
B. Market Analytics

Table 85. UK Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 86. UK Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/ CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 87. UK 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4E. SPAIN

Market Analysis

Table 88. Spanish Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 89. Spanish Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 90. Spanish 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4F. RUSSIA

A. Market Analysis
Current and Future Analysis
Strategic Corporate Development
B. Market Analytics

Table 91. Russian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 92. Russian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 93. Russian 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4G. REST OF EUROPE

A. Market Analysis
Current and Future Analysis
Product Approvals
Strategic Corporate Developments
Mallinckrodt plc – A Major Irish Manufacturer of Nuclear Imaging Agents
B. Market Analytics

Table 94. Rest of Europe Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 95. Rest of Europe Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 96. Rest of Europe 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

A. Market Analysis
Current and Future Analysis
Healthcare Spending in Asia-Pacific: On the Rise
Aging Populace – Potential Opportunities

Table 97. Over 65 Years Individuals as % of Total Population in Select Asian Countries: 2015 (includes corresponding Graph/Chart)

India & China Offer Significant Growth Opportunities
MRI Market in Asia
B. Market Analytics

Table 98. Asia-Pacific Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 99. Asia-Pacific Historic Review for Imaging Agents by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 100. Asia-Pacific 14-Year Perspective for Imaging Agents by Geographic Region - Percentage Breakdown of Dollar Sales for China, India and Rest of Asia-Pacific Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
Table 101. Asia-Pacific Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 102. Asia-Pacific Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 103. Asia-Pacific 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5A. CHINA

A. Market Analysis
Current and Future Analysis
Medical Imaging Equipment Market – An Overview
Increasing Expenditure on Healthcare Sector
Competitive Scenario

Table 104. Leading Players in the Chinese CT Contrast Agents Market (2015): Percentage Breakdown of Value Sales for Select Agents (includes corresponding Graph/Chart)
Table 105. Leading Players in the Chinese MRI Contrast Agents Market (2015): Percentage Breakdown of Value Sales for Select Agents (includes corresponding Graph/Chart)

Strategic Corporate Developments
B. Market Analytics

Table 106. Chinese Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 107. Chinese Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 108. Chinese 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5B. INDIA

A. Market Analysis
India – A High Potential Market
Regulatory Mechanism for Guiding Isotope Production and Distribution
Overview of CT Scanners Market in India
PET/CT Scanning in India Gathers Momentum
J. B. Chemicals and Pharmaceuticals Ltd – A Key Player
B. Market Analytics

Table 109. Indian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 110. Indian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 111. Indian 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5C. REST OF ASIA-PACIFIC

A. Market Analysis
Current and Future Analysis
Korea
Strategic Corporate Development
B. Market Analytics

Table 112. Rest of Asia-Pacific Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/ CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 113. Rest of Asia-Pacific Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 114. Rest of Asia-Pacific 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

6. THE MIDDLE EAST & AFRICA

Market Analysis

Table 115. Middle East & African Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/ CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 116. Middle East & African Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 117. Middle East & African 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

7. LATIN AMERICA

A. Market Analysis
Current and Future Analysis
Private Sector Boosts Healthcare Segment
B. Market Analytics

Table 118. Latin American Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region - Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 119. Latin American Historic Review for Imaging Agents by Geographic Region - Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 120. Latin American 14-Year Perspective for Imaging Agents by Geographic Region - Percentage Breakdown of Dollar Sales for Brazil and Rest of Latin American Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
Table 121. Latin American Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 122. Latin American Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 123. Latin American 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

7A. BRAZIL

Market Analysis

Table 124. Brazilian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 125. Brazilian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 126. Brazilian 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

7B. REST OF LATIN AMERICA

Market Analysis

Table 127. Rest of Latin America Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 128. Rest of Latin America Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 129. Rest of Latin America 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 53 (including Divisions/Subsidiaries - 61)
The United States (33)
Canada (2)
Japan (1)
Europe (19)
  France (3)
  Germany (5)
  The United Kingdom (2)
  Italy (2)
  Rest of Europe (7)
Asia-Pacific (Excluding Japan) (5)
Africa (1)
Skip to top


Ask Your Question

Imaging Agents: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: